Jefferies downgraded Agilon Health to Hold from Buy with a price target of $6.50, down from $25, following a change in analyst coverage. The firm’s long-term conviction in the value-based care opportunity remains intact due to low penetration, payor and government focus on transitioning to value-based frameworks, and an unchanged underlying need for better and lower cost healthcare. However, the analyst is “realistic on near-term headwinds” facing the Medicare Advantage space and says challenges in the public value-based care world “warrant a more selective stance.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AGL:
- Agilon Health Inc (AGL) Q4 Earnings Cheat Sheet
- Agilon Health price target lowered to $9 from $10 at Stifel
- Agilon Health Announces CMO Transition and Interim Appointment
- Agilon Health says Benjamin Kornitzer to transition from role as CMO
- Agilon Health price target lowered to $11 from $23 at RBC Capital